Axis Securities: The brokerage highlighted challenges for Cipla in maintaining a stable market share in Albuterol, though the company is gaining traction in Brovana. Cipla is also gradually building ...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differing views on its performance, citing challenges like ...